ASX Penny Stocks Exhibiting Their Growth Potential

Investors looking for new growth ideas should keep an eye on these ASX listed penny stocks as they move forward with big catalysts and solid expansion plans that give them plenty of room to grow.

Austco Healthcare Limited (ASX: AHC)

is gaining a good amount of traction as it scales its clinical communication and nurse-call technology platform across hospitals.

The company delivered record revenue of $81.4 million in FY25 which is up 40% from last year and EBITDA jumped 62% to $13 million, showing solid operating leverage as margins lifted to 16% from 13.8% the year before.

The company remains disciplined with investment as it increased R&D spend to $4.8 million in FY25 to enhance its nurse-call software, workflow automation and data solutions. 

The balance sheet remains in a good shape with $14.5 million cash on hand and operating cash flow of $13.5 million which sets the stage for growth ahead.

Veris Limited (ASX: VRS)

is slowly shaping itself into more of a high-value digital and spatial data consulting player by moving away from low margin operations and focusing more on top tier clients. 

Revenue reached $97.2 million compared to $92.6 million last year and posted a $2 million profit before tax which is a massive improvement compared to last year’s loss.

Cashflow stayed healthy and the balance sheet looks strong with $16.6 million in cash on hand and net assets rising to $26.1 million. 

The company also returned more than $3.2 million to shareholders via buybacks and paid a 0.2 cent fully franked dividend which signals confidence in the turnaround.

With a clear focus on higher margin advisory work, Veris seems to be laying a solid base for future growth. 

AIC Mines Limited (ASX: A1M)

is steadily building itself by consistent performance at its Eloise mine and good progress at the Jericho development as the company scales production.

A1M delivered another solid year operationally with Eloise meeting guidance again, producing about 12,863 tonnes of copper and 5,955 ounces of gold and generating $79.2 million operating cash flow while producing $27.4 million net mine cash flow.
The balance sheet stayed strong after a $55 million placement, $10 million Special purchase plan and a US$40 million facility from Trafigura, ending the year with around $60.9 million in cash which gives enough flexibility to fund development without pressure.

With copper demand set to rise as electrification and renewable energy infrastructure grow, A1M is well placed to realize its potential.

Nyrada Inc (ASX: NYR)

is going through a major phase as it shifts from discovery to clinical execution with its first-in-class drug Xolatryp which is aimed at protecting the brain and heart after severe injury.

The company finished its Phase I trial with no safety concerns and great pharmacokinetic results.

Nyrada is also in active discussions with global research partners and clinical institutions, aiming to fast-track trial sites as it moves toward human proof-of-concept results.

With current assets of $5.27 million, patents filed globally and a Phase II program ready to begin, Nyrada is positioning itself as a serious emerging player in next-generation neuro-cardiac therapeutics. 

(Source: Company Announcements)